John Newcomb

John has over 25 years of drug discovery and development experience. Prior to Raqia, John was at Takeda in the Immuno-Oncology Drug Discovery Unit where his group contributed to the discovery of both small molecules and biologics that are currently being tested in early clinical trials. John also served as Director at Amgen in the Oncology Discovery group and prior to that as Head of Cell Biology at the start-up biotechnology company, Kinetix Pharmaceuticals. John received his Ph.D. in Microbiology and Immunology from Temple University School of Medicine.